Current and future therapeutic approaches for osteosarcoma

References

• McKenna RJ, Schwinn CP, Soong KY. Sarcomata of the osteogenic series (osteosarcoma, fibrosarcoma, chondrosarcoma, parosteal osteogenic sarcoma, and sarcomata arising in abnormal bone). An analysis of 552 cases. J Bone Joint Surg (Amer). 1966;48-A:1–26.
   Google Scholar
• Marina N, Gebhardt M, Teot L, et al. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004;9:422–441.
   PubMed Web of Science ®Google Scholar
• Data from the American Cancer Society. [cited 2017 Sep 15]. Available from: https://www.cancer.org/cancer/osteosarcoma/about/key-statistics.html
   Google Scholar
• Gurney JG, Swensen AR, Bultreys M, et al. Malignant bone tumors. In: Ries LAG, Smith MA, Gurney JG, editors. Cancer incidence and survival among children and adolescents: United States SEER program 1975-1995. Bethesda, MD: National Cancer Institue; SEER Program. NIH Pub. No. 99-4649. 1999.
   Google Scholar
• Mirabello L, Troisi RJ, Savage S. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer. 2009;115:1531–1542.
   PubMed Web of Science ®Google Scholar
• Mirabello L, Troisi RJ, Savage AR. International osteosarcoma incidence patterns in children and adolescence, middle ages, and elderly persons. Int J Cancer. 2009;125:229–234.
   PubMed Web of Science ®Google Scholar
• Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 2010;8:705–718.
   PubMedGoogle Scholar
• Huvos AG. Osteogenic sarcoma of bones and soft tissues in older persons. A clinic pathologic analysis of 117 patients older than 60 years. Cancer. 1986;57:1442–1449.
   PubMed Web of Science ®Google Scholar
• Fuchs B, Pritchard DJ. Etiology of osteosarcoma. Clin Orthop Relat Res. 2002;397:40–52.
   PubMed Web of Science ®Google Scholar
• Mirabello L, Yeager M, Mai PL, et al. Germline TP53 variants and susceptibility to osteosarcoma. J Natl Cancer Inst. 2015;107.
   Google Scholar
• Luetke A, Meyers PA, Lewis L, et al. Osteosarcoma treatment: where do we stand? A state of the art review. Cancer Treat Rev. 2014;40:523–532.
   PubMed Web of Science ®Google Scholar
• Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–790.
   PubMed Web of Science ®Google Scholar
• Clark JC, Dass CR, Choong P. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol. 2008;134:281–297.
   PubMed Web of Science ®Google Scholar
• Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am. 1997;44:973–989.
   PubMed Web of Science ®Google Scholar
• Kaste SC, Pratt CB, Cain AM, et al. Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis: imaging features. Cancer. 1999;86:1602–1608.
   PubMed Web of Science ®Google Scholar
• Errani C, Longhi A, Rossi G, et al. Palliative therapy for osteosarcoma. Expert Rev Anticancer Ther. 2011;11:217–227.
   PubMed Web of Science ®Google Scholar
• Jaffe N. Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma. Adv Exp Med Biol. 2014;804:1–30.
   PubMed Web of Science ®Google Scholar
• Jaffe N. Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res. 2009;152:239–262.
   PubMedGoogle Scholar
• Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221–1230.
   PubMed Web of Science ®Google Scholar
• Ferrari S, Bacci G, Picci P, et al. Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann Oncol. 1997;8:765–771.
   PubMed Web of Science ®Google Scholar
• Bishop MW, Cheng Y, Krailo MD, et al. Assessing the prognostic significance of histologic response in osteosarcoma: a comparison of outcomes on CCG-782 and INT0133 – a report from the Children’s Oncology Group Bone Tumor Committee. Pediatr Blood Cancer. 2016;63:1737–1743.
   PubMed Web of Science ®Google Scholar
• Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol. 2002;20:426–433.
   PubMed Web of Science ®Google Scholar
• Hagleitner MM, de Bont ES, te Loo DM. Survival trends and long-term toxicity in pediatric patients with osteosarcoma. Sarcoma. 2012;1–5. doi:10.1155/2012/636405
   Google Scholar
• Kempf-Bielack B, Bielack SS, Jürgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group. J Clin Oncol. 2005;23:559–568.
   PubMed Web of Science ®Google Scholar
• Meyers PA. Systemic therapy for osteosarcoma and Ewing sarcoma. Alexandria, VA: 2015 ASCO Annual Meeting Educational Book; 2015.
   Google Scholar
• Anninga JK, Gelberblom H, Fiocco M, et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer. 2011;47:2431–2445.
   PubMed Web of Science ®Google Scholar
• Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective, trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004–2011.
   PubMed Web of Science ®Google Scholar
• Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992;1:5–15.
   Web of Science ®Google Scholar
• Bishop MW, Janeway KA, Gorlick R. Future directions in the treatment of osteosarcoma. Curr Opin Pediatr. 2016;28:26–33.
   PubMed Web of Science ®Google Scholar
• Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomized controlled trial. Lancet Oncol. 2016;17:1396–1408.
   PubMed Web of Science ®Google Scholar
• Schwartz CL, Wexler LH, Krailo MD, et al. Intensified chemotherapy with dexrazoxane cardioprotection in newly diagnosed nonmetastatic osteosarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2016;63:54–61.
   PubMed Web of Science ®Google Scholar
• Daw NC, Neel MD, Rao BN, et al. Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children’s Research Hospital OS99 trial. Cancer. 2011;117:2770–2778.
   PubMed Web of Science ®Google Scholar
• Assi H, Missenard G, Terrier P, et al. Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: results of the Institut Gustave-Roussy phase II trial. Curr Oncol. 2010;17:23–31.
   PubMed Web of Science ®Google Scholar
• Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol. 1996;14:362–372.
   PubMed Web of Science ®Google Scholar
• Bielack SS, Smeland S, Whelan JS, et al. Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon Alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol. 2015;33:2279–2287.
   PubMed Web of Science ®Google Scholar
• Whelan J, Patterson D, Perisoglou M, et al. The role of interferons in the treatment of osteosarcoma. Pediatr Blood Cancer. 2010;54:350–354.
   PubMed Web of Science ®Google Scholar
• Müller CR, Smeland S, Bauer HC, et al. Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncol. 2005;5:475–480.
   Web of Science ®Google Scholar
• Meyers PAand Chou AJ. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma. In: Kleinerman ES, editor. Current advances in osteosarcoma, advances in experimental medicine and biology. Cham: Springer International Publishing; 2014.
   Google Scholar
• Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival – a report from the Children’s Oncology Group. J Clin Oncol. 2008;26:633–638.
   PubMed Web of Science ®Google Scholar
• Campanacci M, Bacci G, Bertoni F, et al. The treatment of osteosarcoma of the extremities: twenty year’s experience at the Istituto Ortopedico Rizzoli. Cancer. 1981;48:1569–1581.
   PubMed Web of Science ®Google Scholar
• Uribe-Botero G, Russell WO, Sutow WW, et al. Primary osteosarcoma of bone. Clinicopathologic investigation of 243 cases, with necropsy studies in 54. Am J Clin Pathol. 1977;67:427–435.
   PubMed Web of Science ®Google Scholar
• Marcove RC, Mike V, Hajek JV, et al. Osteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-five operative cases. J Bone Joint Surg Am. 1970;52:411–423.
   PubMed Web of Science ®Google Scholar
• Jaffe N, Carrasco H, Raymond K, et al. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? Cancer. 2002;95:2202–2210.
   PubMed Web of Science ®Google Scholar
• Bielack S, Jurgens H, Jundt G, et al. Osteosarcoma: the COSS experience. Cancer Treat Res. 2009;152:289–308.
   PubMedGoogle Scholar
• Simon MA, Aschliman MA, Thomas N, et al. Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. J Bone Joint Surg Am. 1986;68:1331–1337.
   PubMed Web of Science ®Google Scholar
• Li X, Zhang Y, Wan S, et al. A comparative study between limb-salvage and amputation for treating osteosarcoma. J Bone Oncol. 2016;5:15–21.
   PubMed Web of Science ®Google Scholar
• He X, Gao Z, Xu H, et al. A meta-analysis of randomized control trials of surgical methods with osteosarcoma outcomes. J Orthop Surg Res. 2017;12:5.
   PubMed Web of Science ®Google Scholar
• Kawaguchi N, Ahmed AR, Matsumoto S, et al. The concept of curative margin in surgery for bone and soft tissue sarcoma. Clin Orthop Relat Res. 2004;419:165–172.
   Google Scholar
• Geller DS, Singh MY, Zhang W, et al. Development of a model system to evaluate local recurrence in osteosarcoma and assessment of the effects of bone morphogenetic protein-2. Clin Cancer Res. 2015;21:3003–3012.
   PubMed Web of Science ®Google Scholar
• Grimer RJ, Taminiau AM, Cannon SR. Surgical Subcommitte of the European osteosarcoma I. Surgical outcomes in osteosarcoma. J Bone Joint Surg Br. 2002;84:395–400.
   PubMedGoogle Scholar
• Iwata S, Ishii T, Kawai A, et al. Prognostic factors in elderly osteosarcoma patients: a multi-institutional retrospective study of 86 cases. Ann Surg Oncol. 2014;21:263–268.
   PubMed Web of Science ®Google Scholar
• Bacci G, Forni C, Longhi A, et al. Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J Surg Oncol. 2007;96:118–123.
   PubMed Web of Science ®Google Scholar
• Capanna R, Scoccianti G, Frenos F, et al. What was the survival of megaprostheses in lower limb reconstructions after tumor resections? Clinical Orthop Relat Res. 2015;473:820–830.
   PubMed Web of Science ®Google Scholar
• Schwartz AJ, Kabo JM, Eilber FC, et al. Cemented distal femoral endoprostheses for musculoskeletal tumor: improved survival of modular versus custom implants. Clinical Orthop Relat Res. 2010;468:2198–2210.
   PubMed Web of Science ®Google Scholar
• Healey JHMC, Athanasian EA, Boland PJ. Compress knee arthroplasty has 80% 10-year survivorship and novel forms of bone failure. Clin Orthop Relat Res. 2013;471:774–783.
   PubMed Web of Science ®Google Scholar
• Mankin HJ, Gebhardt MC, Jennings LC, et al. Long-term results of allograft replacement in the management of bone tumors. Clin Orthop Relat Res. 1996;324:86–97.
   PubMed Web of Science ®Google Scholar
• Ortiz-Cruz E, Gebhardt MC, Jennings LC, et al. The results of transplantation of intercalary allografts after resection of tumors. A long-term follow-up study. J Bone Joint Surg Am. 1997;79:97–106.
   PubMed Web of Science ®Google Scholar
• Brigman BE, Hornicek FJ, Gebhardt MC, et al. Allografts about the knee in young patients with high-grade sarcoma. Clin Orthop Relat Res. 2004;421:232–239.
   Web of Science ®Google Scholar
• Hornicek FJ, Gebhardt MC, Tomford WW, et al. Factors affecting nonunion of the allograft-host junction. Clin Orthop Relat Res. 2001;382:87–98.
   PubMed Web of Science ®Google Scholar
• Lord CF, Gebhardt MC, Tomford WW, et al. Infection in bone allografts. Incidence, nature, and treatment. J Bone Joint Surg Am. 1988;70:369–376.
   PubMed Web of Science ®Google Scholar
• Dick HM, Strauch RJ. Infection of massive bone allografts. Clin Orthop Relat Res. 1994;306:46–53.
   PubMed Web of Science ®Google Scholar
• Ceruso M, Falcone C, Innocenti M, et al. Skeletal reconstruction with a free vascularized fibula graft associated to bone allograft after resection of malignant bone tumor of limbs. Handchir Mikrochir Plast Chir. 2001;33:277–282.
   PubMedGoogle Scholar
• Chang DW, Weber KL. Segmental femur reconstruction using an intercalary allograft with an intramedullary vascularized fibula bone flap. J Reconstr Microsurg. 2004;20:195–199.
   PubMed Web of Science ®Google Scholar
• Moran SL, Shin AY, Bishop AT. The use of massive bone allograft with intramedullary free fibular flap for limb salvage in a pediatric and adolescent population. Plast Reconstr Surg. 2006;118:413–419.
   PubMed Web of Science ®Google Scholar
• Chou AJ, Kleinerman ES, Krailo MD, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group. Cancer. 2009;115:5339–5348.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–7109.
   PubMed Web of Science ®Google Scholar
• Keir ST, Maris JM, Lock R, et al. Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010;55:1126–1133.
   PubMed Web of Science ®Google Scholar
• Pignochino Y, Grignani G, Cavalloni G, et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer. 2009;8:118.
   PubMed Web of Science ®Google Scholar
• Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2012;23:508–516.
   PubMed Web of Science ®Google Scholar
• Grignani G, Palmerini E, Ferraresi V, et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 2015;16:98–107.
   PubMed Web of Science ®Google Scholar
• Lagmay JP, Krailo MD, Dang H, et al. Outcome of patients with recurrent osteosarcoma enrolled in seven phase II trials through Children’s Cancer Group, Pediatric Oncology Group, and Children’s Oncology Group: learning from the past to move forward. J Clin Oncol. 2016;34:3031–3038.
   PubMed Web of Science ®Google Scholar
• Mori K, Le Goff B, Berreur M, et al. Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. J Pathol. 2007;211:555–562.
   PubMed Web of Science ®Google Scholar
• Lee JA, Jung JS, Kim DH, et al. RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma. Pediatr Blood Cancer. 2011;56:738–743.
   PubMed Web of Science ®Google Scholar
• Piperno-Neumann S, Le Deley MC, Rédini F, et al. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016;17:1070–1080.
   PubMed Web of Science ®Google Scholar
• Heiner JP, Miraldi F, Kallick S, et al. Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma. Cancer Res. 1987;47:5377–5381.
   PubMed Web of Science ®Google Scholar
• Roth M, Linkowski M, Tarim J, et al. Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. Cancer. 2014;120:548–554.
   PubMed Web of Science ®Google Scholar
• Poon VI, Roth M, Piperdi S, et al. Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma. Clin Sarcoma Res. 2015;5:4.
   PubMed Web of Science ®Google Scholar
• Champiat S, Ferté C, Lebel-Binay S, et al. Exomics and immunogenics: bridging mutational load and immune checkpoints efficacy. Oncoimmunology. 2014;3:e27817.
   PubMed Web of Science ®Google Scholar
• Koirala P, Roth ME, Gill J, et al. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci Rep. 2016;6:30093.
   PubMed Web of Science ®Google Scholar
• Sundara YT, Kostine M, Cleven AH, et al. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. Cancer Immunol Immunother. 2017;66:119–128.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Jin Z, Zhang M, et al. Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis. Oncotarget. 2017;8:59570–59580.
   PubMed Web of Science ®Google Scholar
• Lussier DM, O’Neill L, Nieves LM, et al. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J Immunother. 2015;38:96–106.
   PubMed Web of Science ®Google Scholar
• Lussier DM, Johnson JL, Hingorani P, et al. Combination immunotherapy with alpha-CTLA-4 and alpha-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. J Immunother Cancer. 2015;3:21.
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Burgess MA, Crowley J, et al. Safety and efficacy of PD-1 blockade using pembrolizuma in patients with advance soft tissue (STS) and bone sarcomas (BS): results of SARC028-a multicenter phase II study. Am Soc Clin Oncol. 2016 Chicago, IL: Journal of Clinical Oncology. Abstract 11006.
   Web of Science ®Google Scholar
• Paoluzzi L, Cacavio A, Ghesani M, et al. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res. 2016;6:24.
   PubMed Web of Science ®Google Scholar
• Gomez-Brouchet A, Illac C, Gilhodes J, et al. CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: an immunohistochemical analysis of the biopsies from the French OS2006 phase 3 trial. Oncoimmunology. 2017;6:1–13.
   Web of Science ®Google Scholar
• Isakoff MS, Bielack SS, Meltzer P, et al. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33:3029–3035.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Office of Cancer Genomics. TARGET: therapeutically applicable research to generate effective treatments. Available from: https://ocg.cancer.gov/programs/target
   Google Scholar
• Chen X, Bahrami A, Pappo A, et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep. 2014;7:104–112.
   PubMed Web of Science ®Google Scholar
• Cartiaux O, Docquier PL, Paul L, et al. Surgical inaccuracy of tumor resection and reconstruction within the pelvis: an experimental study. Acta Orthop. 2008;79:695–702.
   PubMed Web of Science ®Google Scholar
• Jeys L, Matharu GS, Nandra RS, et al. Can computer navigation-assisted surgery reduce the risk of an intralesional margin and reduce the rate of local recurrence in patients with a tumour of the pelvis or sacrum? Bone Joint J. 2013;95-B:1417–1424.
   PubMed Web of Science ®Google Scholar
• Gerbers JG, Stevens M, Ploegmakers JJ, et al. Computer-assisted surgery in orthopedic oncology. Acta Orthop. 2014;85:663–669.
   PubMed Web of Science ®Google Scholar
• Sternheim A, Daly M, Qiu J, et al. Navigated pelvic osteotomy and tumor resection: a study assessing the accuracy and reproducibility of resection planes in Sawbones and cadavers. J Bone Joint Surg Am. 2015;97:40–46.
   PubMed Web of Science ®Google Scholar
• Khan F, Pearle A, Lightcap C, et al. Haptic robot-assisted surgery improves accuracy of wide resection of bone tumors: a pilot study. Clin Orthop Relat Res. 2013;471:851–859.
   PubMed Web of Science ®Google Scholar
• Bellanova L, Paul L, Docquier PL. Surgical guides (patient-specific instruments) for pediatric tibial bone sarcoma resection and allograft reconstruction. Sarcoma. 2013;2013:787653.
   PubMedGoogle Scholar
• Wong KC, Kumta SM, Sze KY, et al. Use of a patient-specific CAD/CAM surgical jig in extremity bone tumor resection and custom prosthetic reconstruction. Comput Aided Surg. 2012;17:284–293.
   PubMed Web of Science ®Google Scholar
• Khan FA, Lipman JD, Pearle AD, et al. Surgical technique: computer-generated custom jigs improve accuracy of wide resection of bone tumors. Clin Orthop Relat Res. 2013;471:2007–2016.
   PubMed Web of Science ®Google Scholar
• Jeys LM, Kulkarni A, Grimer RJ, et al. Endoprosthetic reconstruction for the treatment of musculoskeletal tumors of the appendicular skeleton and pelvis. J Bone Joint Surg Am. 2008;90:1265–1271.
   PubMed Web of Science ®Google Scholar
• Wafa H, Grimer RJ, Reddy K, et al. Retrospective evaluation of the incidence of early periprosthetic infection with silver-treated endoprostheses in high-risk patients: case-control study. Bone Joint J. 2015;97-B:252–257.
   PubMed Web of Science ®Google Scholar
• Hardes J, von Eiff C, Streitbuerger A, et al. Reduction of periprosthetic infection with silver-coated megaprostheses in patients with bone sarcoma. J Surg Oncol. 2010;101:389–395.
   PubMed Web of Science ®Google Scholar
• Bell RS, Roth YF, Gebhardt MC, et al. Timing of chemotherapy and surgery in a murine osteosarcoma model. Cancer Res. 1988;48:5533–5538.
   PubMed Web of Science ®Google Scholar
• Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003;21:1574–1580.
   PubMed Web of Science ®Google Scholar